U.K. Atrial Fibrillation Devices Market

U.K. Atrial Fibrillation Devices Market

Introduction

Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but the most common ones associated with it are palpitations, fainting, congestive chest pain or failure of the heart. The confirmation for AF is obtained by an electrocardiogram which exhibits an absence of the wave and irregular rate of ventricular contractions. These irregularities in the regular cardio electric impulses of the sino-atrial node are the result of interference from chaotic electric impulses generating from roots of pulmonary veins consequently leading to the conduction of an irregular heartbeat. Atrial fibrillation based on the severity of the condition is divided into three types namely paroxysmal (symptoms stop within 24 hours), persistent (symptoms continue for more than a week), and permanent (long term) atrial fibrillation. According to WHO, atrial fibrillation is the most common type of arrhythmia. This report offers detailed coverage of Atrial Fibrillation devices industry and main market trends. The report forecast U.K. Atrial Fibrillation devices market to grow to reach 2,691.6 million USD in 2020.

key impacts on the industry:

• RAW MATERIAL CRUNCH
• SHUTDOWN OF THE PLANTS
• MATERIAL FLUCTUATIONS

Key Segmentations Cardiologists reported that they are treating increasing numbers of patients with paroxysmal and persistent AF

• The cardiac rhythm management is expected to witness fastest market growth owing to the emergence of implantable cardiac monitors (ICMs) and worldwide adoption of other cardiac monitors such as holter monitor, event recorder, mobile cardiac telemetry (MCT) to monitor heart rhythms

Key Development Involvement of the biotech companies Product formulationsInvestment for improving content Price fluctuations Energy price impacting the overall industry

In May 2020, CardioFocus, Inc. received the U.S. Food and Drug Administration approval for the next generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation.Allied industry Data The ardic arrhythmia market is allied to the Atrial fibrillation devices market. Atrial fibrillation (AF) is the most common cardiac arrhythmia, occurring in 1.5-2.0% of the general population. The presence of AF is associated with unfavourable prognosis.